Pipeline

R&D na Sorrento yana mai da hankali kan haɓaka sabbin abubuwa a cikin COVID-19, maganin cutar kansa, cikakken kula da ciwo da cututtukan autoimmune.

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
Shirye-shiryen COVID-19  

COVISTIX (diagnostic) Gwajin Antigen gaggawa

*

Izinin Amfani da Gaggawa (EUA) a Mexico (COFEPRIS), Brazil (ANVISA), da CE Alama a Turai

COVIMARK™ (diagnostic) Gwajin Antigen gaggawa

*

Aikace-aikacen da aka ƙaddamar a cikin Amurka da Kanada don Izinin Amfani da Gaggawa (EUA)

COVISHIELD™ (maganin magani) Neutralizing Antibody (IN) a cikin marasa lafiya da marasa lafiya

40%*

COVISHIELD™ (maganin magani) Neutralizing Antibody (IV) a cikin marasa lafiya da marasa lafiya

20%*

FUJOVEE (Abivertinib) Mummunan COVID-19 a cikin Marasa lafiya na ICU

82%*

Muhimmin Gwajin da ke jiran Cirewar FDA

OQORY™ (COVI-MSC) ARDS saboda COVID-19 a cikin marasa lafiya na ICU

82%*

Muhimmin gwaji a Brazil

Mpro Mai hanawa (kwayoyin baka) Anti rigakafi

40%*

Omicron mRNA rigakafin maganin

20%*

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
immunotherapy  

FUJOVEE (Abivertinib) Bayanin NSCLC

82%*

FUJOVEE (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE (Abivertinib) prostate

20%*

FUJOVEE (Abivertinib) Lupus

20%*

FUJOVEE (Abivertinib) MS

20%*

FUJOVEE (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*A cikin haɗin gwiwa tare da Lee's Pharm a China

PD-L1 (STI-3031)** Cercical Cancer

82%*

** A Amurka kuma tare da haɗin gwiwar ImmuneOncia a Koriya

CD47 Tumburai masu ƙarfi

40%*

CD38 DAR-T Multiye Myeloma

40%*

Saukewa: CD38D Amyloidosis, Multiple Myeloma, T-ALL, da esophageal

40%*

TROP2 ADC* Tumburai masu ƙarfi

40%*

* A kasar Sin

Seprehvec™ oncolytic cutar Ciwon Ciwon Ciki; Ciwon daji na CNS

40%*

Farashin BCMA Tuwon Ruwa

20%*

Bevacizumab-ADNAB™ Ciwon daji na Endometrial

40%*

A haɗin gwiwa tare da Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Ciwon daji

40%*

A haɗin gwiwa tare da Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

A haɗin gwiwa tare da Mayo Clinic
Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
Pain  

ZTlido™ 1.8%
Postherpetic Neuralgia - PHN

99.8%*

SP-102 (SEMDEXA) Lumbar Radicular / Sciatica Pain

82%*

SP-103 (Tsarin Topical Lidocaine 5.4%) Ciwon Baya

20%*

SP-104 (An jinkirta fashe Low Dose Naltrexone) Fibromyalgia

20%*

RTX (resiferatoxin)
Epidural allura
Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Kankara

60.3%*

Sunan marayu

RTX (resiferatoxin)
Hanyar intra-articular
Matsakaici zuwa Ƙunƙarar Ƙifin OA

60.2%*

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
Bayarwa Lymphatic  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

A haɗin gwiwa tare da Mayo Clinic
Shirye-shiryen COVID-19
Mabuɗin Shirye-shirye (Alamar) Phase
COVISTIX (diagnostic) FDA EU
COVIMARK™ (diagnostic) FDA EU
COVISHIELD™ (maganin magani) PH I
COVISHIELD™ (maganin magani) Preclinical
FUJOVEE (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (kwayoyin baka) (anti-viral) Ph I
Omicron mRNA rigakafin (alurar rigakafi) Preclinical
immunotherapy
Mabuɗin Shirye-shirye (Alamar) Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II
FUJOVEE™ (Abivertinib) (Prostate) Preclinical
FUJOVEE™ (Abivertinib) (Lupus) Preclinical
FUJOVEE™ (Abivertinib) (MS) Preclinical
FUJOVEE™ (Abivertinib) (GvHD) Preclinical
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Cancer mahaifa) Ph III
CD47 (Tsarin Tumor) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
Saukewa: CD38D (Amyloidosis, Multiple Myeloma, T-ALL, da esophageal) Ph I
TROP2 ADC* (Tsarin Tumor) Ph I
Seprehvec™ oncolytic cutar (Tsarin Ciwon Ciwon Ciki; Ciwon Ciwon Ciki) PH I
Farashin BCMA (Magungunan Liquid) Preclinical
Bevacizumab-ADNAB™ (Cancer Endometrial) Ph I
Bevacizumab-ADNAB™ (Cancer Ovarian) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Pain
Mabuɗin Shirye-shirye (Alamar) Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
SP-102 (SEMDEXA) Ph III
SP-103 (Tsarin Topical Lidocaine 5.4%) Preclinical
SP-104 (An jinkirta fashe Low Dose Naltrexone) Preclinical
RTX (resiniferatoxin) allurar epidural (Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciki) Ph II
RTX (resiniferatoxin) Hanya ta ciki (Matsakaici zuwa Ciwon Knee mai tsanani na OA) Ph II
Bayarwa Lymphatic
Mabuɗin Shirye-shirye (Alamar) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I